ODYSSEY Outcomes: Alirocumab lowers CV events in ACS population

12:22 EST 10 Mar 2018 | Healio

ORLANDO, Fla. — Reducing LDL to very low levels with the PCSK9 inhibitor alirocumab lowered risk for major adverse CV events and all-cause mortality in patients with ACS on statin therapy, according to anticipated results of the ODYSSEY Outcomes trial presented as a late-breaking clinical trial at the American College of Cardiology Scientific Session.
For the primary outcome of major adverse CV events, defined as CHD death, nonfatal MI, ischemic stroke or unstable angina requiring hospitalization, alirocumab (Praluent, Sanofi/Regeneron) conferred a 15% risk reduction compared with

Original Article: ODYSSEY Outcomes: Alirocumab lowers CV events in ACS population


More From BioPortfolio on "ODYSSEY Outcomes: Alirocumab lowers CV events in ACS population"

Quick Search


Relevant Topics

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...

Cholesterol is a waxy steroid metabolite found in the cell membranes and transported in the blood plasma. It is an important structural component of mammalian cell membranes, where it is establishes proper membrane permeability and fluidity. Cholesterol ...